Drug Profile
Sarcoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center
Alternative Names: MV-Sarc; Trivalent ganglioside vaccineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines; Conjugate vaccines; Monoclonal antibodies; Vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sarcoma
Most Recent Events
- 10 Mar 2017 MabVax Therapeutics completes a phase II trial in Sarcoma in USA (SC) (NCT01141491)
- 07 Apr 2015 Phase II development is ongoing in USA
- 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik